Besifloxacin
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB06771 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 29 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | bronchitis | KG + DL |
| 2 | postinfectious vasculitis | KG + DL |
| 3 | post-bacterial disorder | KG + DL |
| 4 | post-infectious syndrome | KG + DL |
| 5 | infective urethral stricture | KG + DL |
| 6 | Chagas cardiomyopathy | KG + DL |
| 7 | infection-related hemolytic uremic syndrome | KG + DL |
| 8 | otitis externa | KG + DL |
| 9 | tinea corporis | KG + DL |
| 10 | catatrichy | KG + DL |
| 11 | pseudomembranous conjunctivitis | KG + DL |
| 12 | acute hemorrhagic conjunctivitis | KG + DL |
| 13 | Angelucci syndrome | KG + DL |
| 14 | parasitic conjunctivitis | KG + DL |
| 15 | chronic follicular conjunctivitis | KG + DL |
| 16 | serous conjunctivitis except viral | KG + DL |
| 17 | conjunctival folliculosis | KG + DL |
| 18 | infectious mononucleosis | KG + DL |
| 19 | keratosis follicularis spinulosa decalvans, autosomal dominant | KG + DL |
| 20 | ophthalmic herpes zoster | KG + DL |
| 21 | Laubry-Pezzi syndrome | KG + DL |
| 22 | orbital cellulitis | KG + DL |
| 23 | amebic dysentery | KG + DL |
| 24 | pulmonary valve disease | KG + DL |
| 25 | papillary conjunctivitis | KG + DL |
| 26 | heart neoplasm | KG + DL |
| 27 | skin disease caused by infection | KG + DL |
| 28 | pityriasis versicolor | KG + DL |
| 29 | genetic syndromic Pierre Robin syndrome | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.